✦ LIBER ✦

Re: Docetaxel and Atrasentan versus Docetaxel and Placebo for Men with Advanced Castration-Resistant Prostate Cancer (SWOG S0421): A Randomised Phase 3 Trial

✍ Scribed by Taneja, Samir S.

Book ID: 122298553
Publisher: Lippincott Williams and Wilkins
Year: 2014
Tongue: English
Weight: 68 KB
Volume: 191
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2013.11.085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel and atrasentan versus docetaxe

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

✍ Quinn, David I; Tangen, Catherine M; Hussain, Maha; Lara, Primo N; Goldkorn, Ami 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 261 KB

2-weekly versus 3-weekly docetaxel to tr

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

✍ Kellokumpu-Lehtinen, Pirkko-Liisa; Harmenberg, Ulrika; Joensuu, Timo; McDermott, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 206 KB

Docetaxel and dasatinib or placebo in me

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

✍ Araujo, John C; Trudel, Géralyn C; Saad, Fred; Armstrong, Andrew J; Yu, Evan Y; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 703 KB

Re: Aflibercept versus Placebo in Combin

Re: Aflibercept versus Placebo in Combination with Docetaxel and Prednisone for Treatment of Men with Metastatic Castration-Resistant Prostate Cancer (VENICE): A Phase 3, Double-Blind Randomised Trial

✍ Taneja, Samir S. 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 59 KB

Circulating Tumor Cell Counts Are Progno

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

✍ Goldkorn, A.; Ely, B.; Quinn, D. I.; Tangen, C. M.; Fink, L. M.; Xu, T.; Twardow 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 180 KB

Aflibercept versus placebo in combinatio

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

✍ Tannock, Ian F; Fizazi, Karim; Ivanov, Sergey; Karlsson, Camilla Thellenberg; Fl 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 310 KB